Butterfly and renal cell cancer: Out of chaos comes order

Journal of Clinical Oncology

Volumn 32, Issue 27, 2014, Pages 3083-

  Procopio, Giuseppe ^a   Verzoni, Elena ^a   De Braud, Filippo ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AXITINIB; MAMMALIAN TARGET OF RAPAMYCIN; PAZOPANIB; SUNITINIB; TEMSIROLIMUS; ANGIOGENESIS INHIBITOR; PROTEIN KINASE INHIBITOR;

CANCER CHEMOTHERAPY; CANCER PATIENT; CHAOS THEORY; CLINICAL PRACTICE; DRUG TOLERABILITY; HUMAN; KIDNEY CARCINOMA; LETTER; CARCINOMA, RENAL CELL; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MALE; NEPHRECTOMY;

ANGIOGENESIS INHIBITORS; CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MALE; NEPHRECTOMY; PROTEIN KINASE INHIBITORS;

EID: 84907211066     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.56.4757     Document Type: Letter

References (5)

1. Hwang C, Heath EI: The judgment of Paris: Treatment dilemmas in advanced renal cell carcinoma. J Clin Oncol 32:729-734, 2014
2. Rini BI, Bellmunt J, Clancy J, et al: Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT Trial. J Clin Oncol 32:752-759, 2014
3. Hutson TE, Escudier B, Esteban E, et al: Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 32:760-767, 2014
4. Porta C: Entropy increases in kidney cancer treatment, but a bit of simplicity may emerge from chaos. Eur Urol 60:1171-1172, 2011
5. Ryan CW: Systemic therapies in advanced renal cell cancer: Current status. Presented at the 46th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 4-8, 2010